Nathalie Rivard

Prix et distinctions

• (2025) Canada Research Chair in colorectal and inflammatory cell signalling. IRSC. (Distinction).
• (2022) Editorial board of Cancers. (Distinction).
• (2020) Editorial Board Member of World J Gastrointestinal and Pathophysiology. World Jounal of Gastrointestinal Pathophysiology. (Distinction).
• (2018) Canada Research Chair in colorectal and inflammatory cell signalling. Canada research Chair Program. (Distinction).
• (2018) Editorial board of International Journal of Oncology. (Distinction).
• (2017) Editorial board de Médecine Sciences. Médecine Sciences. (Distinction).
• (2017) Editorial Board of Gastrointestinal Cancer: Targets and Therapy. Gastrointestinal Cancer: Targets and Therapy. (Distinction).
• (2013) Research Excellence Award from the Canadian Association of Gastroenterology. Canadian Association of Gastroenterology. (Prize / Award).
• (2012) Canada Research Chair in Digestive physiopathology and signalling. Canada research Chair Program. (Distinction).
• (2006) Pierre-et-Danielle-Bourgaux Prize. Université de Sherbrooke. (Prize / Award).
• (2006) Young Investigator Award of the Canadian Association of Gastroenterology. Canadian Association of Gastroenterology. (Prize / Award).
• (2004) Researcher of the week. Canadian for Health Research. (Distinction).
• Editorial board of International Journal of Oncology. International Journal of Oncology. (Distinction).
• Etienne-LeBel award. Université de Sherbrooke. (Prize / Award).
• Fellow from American Gastroenterological Association. American Gastroenterological Association. (Distinction).
• RECMUS Prize. Université de Sherbrooke. (Prize / Award).

Financement

• Grant. (Awarded). Principal Applicant. Understanding the interplay between Shp-2 and microbiota in colonic inflammation. Canadian Institutes of Health Research (CIHR). Volet Projet. 994 500 $. (2023-2028)
• Grant. (Awarded). Co-investigator. Mécanismes moléculaires orchestrant la transition épithélio-mésenchymateuse.. Fonds de recherche du Québec - Nature et technologies (FRQNT). Subvention d'équipe. 150 000 $. (2023-2026)
• Research Chair. (Awarded). Principal Investigator. Canada Research Chair in colorectal cancer and inflammatory cell signaling. Canadian Institutes of Health Research (CIHR). Canada Research Chair. 1 400 000 $. (2018-2025)
• Grant. (Awarded). Principal Investigator. A critical role for DUal Specificity Phosphatase 4 in intestinal oncogenesis?. Canadian Institutes of Health Research (CIHR). Operating grant. 803 250 $. (2019-2024)
• Grant. (Awarded). Principal Investigator. Exploring the role of Shp-2 in APC-mutated colorectal cancer. Cancer Research Society (The). Operating grant. 120 000 $. (2021-2023)
• Grant. (Completed). Principal Investigator. Understanding the interplay between Shp-2 and microbiota in colonic inflammation.. Canadian Institutes of Health Research (CIHR). Projet Grant-Bridge. 100 000 $. (2021-2022)
• Grant. (Completed). Principal Investigator. Role of SHP-2 in the pathogenesis of inflammatory bowel diseases. (2015-2021)
• Grant. (Completed). Principal Investigator. A critical role for DUal Specificity Phosphatase 4 in intestinal oncogenesis?. Canadian Institutes of Health Research (CIHR). Project Grant-Bridge. 100 000 $. (2018-2019)
• Grant. (Completed). Principal Investigator. Role of SHP-1 in the control of intestinal epithelial proliferation and differentiation. Natural Sciences and Engineering Research Council of Canada (NSERC). Découverte. 216 000 $. (2012-2019)
• Fellowship. (Completed). Principal Investigator. Chaire de Recherche du Canada sur la signalisation du cancer colorectal et de l'inflammation intestinale. (2011-2018)
• Grant. (Completed). Co-applicant. In vivo studies of autophagy: from the model organism to human organoids. Canada Foundation for Innovation (CFI). Leaders. 372 960 $. (2017-2018)
• Grant. (Completed). Co-investigator. The Sherbrooke Personalized Colorectal Cancer Avatar Models Initiative (COLOR project). MERCK-Faculté de médecine et des sciences de la santé de l'Université de Sherbrooke. Programme de subvention MERCK Sharp & Dohme. 250 000 $. (2016-2018)
• Grant. (Completed). Co-investigator. Targeting GPCRs and extracellular proteases for the treatment of colorectal cancer. (2015-2017)
• Grant. (Completed). Principal Investigator. Regulation and role of the ERK signaling in colorectal carcinogenesis. (2012-2017)
• Grant. (Completed). Co-investigator. La culture organoïde : le chainon manquant pour le pronostic et le traitement optimisé des cancers du côlon, de la prostate et du pancréas. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Projets structurants. 50 000 $. (2016-2017)
• Grant. (Completed). Principal Investigator. Understanding the dual nature of SHP-2 tyrosine phosphatase in colorectal cancer. (2014-2016)
• Grant. (Completed). Principal Investigator. SHP-2 est-il un nouveau facteur de susceptibilité génétique pour les maladies inflammatoires de l’intestin?. (2014-2016)
• Grant. (Completed). Co-investigator. Mesenchymal-associated PTEN signaling in intestinal tumor initiation and progression.. (2012-2014)
• Grant. (Completed). Principal Investigator. Role of the tyrosine phosphatase SHP-2 in intestinal inflammation. (2010-2013)
• Grant. (Completed). Co-investigator. CIHR Team on Digestive Epithelium. (2007-2012)
• Fellowship. (Completed). Principal Investigator. Chaire de Recherche du Canada en Physiopathologie digestive et Signalisation. (2007-2012)
• Grant. (Completed). Principal Investigator. Caractérisation des rôles des MAP kinases ERKs et de la protéine d'échafaudage hDlg dans le contrôle de l'équilibre entre prolifération et différenciation des cellules épithéliales de l'intestin. (2006-2011)
• Grant. (Completed). Principal Investigator. Rôle d'E2F4 dans la tumorigenèse épithéliale intestinale. (2010-2011)

Publications

Articles de revue

• Gagné-Sansfaçon J, A Côté-Biron*, M-J Langlois, C-K Qu, S Geha, M Brunet, and N Rivard. (2024). Oncogene (Submitted).
• Valdes J, J Gagné-Sansfaçon, V Reyes, A Armas, G Marrero, M Mayo-Muamba, S Ramanathan, N Perreault, S Ilangumaran, N Rivard, L-C Fortier, A Menedez. (2023). Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high-fat/high-cholesterol diet. Anatomical Records 306 1165-1183. DOI. (Published).
• Lannoy V*, A Côté-Biron*, C Asselin, N Rivard. (2023). TIRAP, TRAM and Toll-Like Receptors: the untold story. Mediators of Inflammation Mars 2899271. DOI. (Published).
• Girondel C, Lévesque K, Langlois MJ*, Pasquin S, Saba-El-Leil MK, Rivard N, Friesel R, Servant MJ, Gauchat JF, Lesage S, Meloche S. (2021). Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis. Oncogene 40 (2), 452-464. (Published).
• St-Jean S, AC De Castro, M Lecours, C Jones, N Rivard, J Auwerx, F Rodier, N Perreault, and F Boudreau. (2021). NCOR1 Sustains Colorectal Cancer Cell Growth and Protects against Cellular Senescence. Cancers 13 (17), 4414. (Published).
• Lannoy V*, A Côté-Biron*, C Asselin, N Rivard. (2021). Phosphatases in Toll-Like Receptors signaling: the unfairly-forgotten. Cell Communication and Signaling 19 (1), 10-30. (Published).
• Raisch J*, A Côté-Biron*, MJ Langlois*, C Leblanc*, N Rivard. (2021). Unveiling the roles of Low-Density Lipoprotein Receptor-Related Protein 6 in intestinal homeostasis, regeneration and oncogenesis. Cells 10 (7), 1792. (Published).
• Raisch J*, A Côté-Biron* and N Rivard. (2019). Cancers 11 (8), E1162. (Published).
• Lauzier A., Normandeau-Guimond J., Vaillancourt-Lavigueur V*., Boivin V., Charbonneau M., Rivard N., Scott MS., Dubois CM., Jean S. (2019). Colorectal cancer cells respond differentially to autophagy inhibition in vivo. Scientific Reports 9 (1), 11316. (Published).
• Beaudry K*, MJ Langlois, A Montagne*, S Cagnol*, JC Carrier, N Rivard. (2019). Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis. Journal of Cell Physiology 234 (5), 6731-6745. (Published).
• Jodoin, Rl, J Carrier, N Rivard, M Bisaillon, JP Perreault. (2019). G-quadruplex located in the 5’UTR of the BAG-1 mRNA affects both its cap-dependent and cap-independent translation through global secondary structure maintenance. Nucleic Acid Research 47 (19), 10247-10266. (Published).
• Langlois MJ*, R Servant, V Reyes-Nicolas, C Jones, SAB Roy, M Paquet, JC Carrier, N Rivard, F Boudreau, N Perreault. (2019). Loss of PTEN Signaling in Foxl1+ Mesenchymal Telocytes Initiates Spontaneous Colonic Neoplasia in Mice. Cell Mol Gastroenterology Hepatol 8 (3), 530-533. (Published).
• Gagné-Sansfaçon J*, A Langlois*, G Coulombe*, S Tremblay, V Vaillancourt-Lavigueur*, MJ Langlois, CK Qu, A Menendez, N Rivard. (2019). The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration. Journal of Pathology 247 (1), 135-146. (Published).
• Leblanc C*, MJ Langlois, G Coulombe*, V Vaillancourt-Lavigureur*, JC Carrier, F Boudreau, and N Rivard. (2017). Epithelial Src Homology region 2 domain-containing Phosphatase-1 restrains intestinal growth, secretory cell differentiation and tumorigenesis. Faseb J 31 3512-3526. (Published).
• Bian B*, S Mongrain, S Cagnol*, MJ Langlois, J Boulanger*, G Bernatchez JC Carrier, F Boudreau, N Rivard. (2016). Cathepsin B promotes colorectal tumorigenesis, cell invasion and metastasis. Molecular Carcinogenesis 55 671-687. (Published).
• Gonneaud A, Turgeon N, Boudreau F, Perreault N, Rivard N, Asselin C. (2016). Distinct Roles for Intestinal Epithelial Cell-Specific Hdac1 and Hdac2 in the Regulation of Murine Intestinal Homeostasis. J Cell Physiology 231 (2), 436-448. (Published).
• Coulombe G*, Rivard N. (2016). New and unexpected biological functions for SHP-2 tyrosine phosphatase in the gastrointestinal tract. Cellular and Molecular Gastroenterology and Hepatology 2 (1), 11-21. (Published).
• Gagné-Sansfaçon J*, G Coulombe*, MJ Langlois, A Langlois*, M Paquet, J Carrier, GS Feng, CK Qu, N Rivard. (2016). SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. Oncotarget 7 (40), 65676-65695. (Published).
• Coulombe G*, A Langlois*, G De Palma, MJ Langlois, JL McCarville, J Gagné-Sanfaçon*, N Perreault, GS Feng, P Bercik, F Boudreau, EF Verdu and N Rivard. (2016). SHP-2 phosphatase prevents colonic inflammation by controlling secretory celldifferentiation and maintaining host-microbiota homeostasis. Journal Cellular Physiology 231 (11), 2529-2540. (Published).
• Lemieux E*, S Cagnol*, K Beaudry*, J Carrier, N Rivard. (2015). Oncogenic KRAS signalling promotes Wnt/b-catenin pathway through LRP6 in colorectal cancer. Oncogene 34 (38), 4914-4927. (Published).
• Paquin MC*, Cagnol S*, Carrier JC, Leblanc C*, Rivard N. (2013). ERK-associated changes in E2F4 phosphorylation, localization and transcriptional activity during mitogenic stimulation in human intestinal epithelial crypt cells. BMC cell biology 14 33-42. (Published).
• Bernatchez G , Giroux V , Lassalle T , Carpentier AC , Rivard N , Carrier JC. (2013). ERRalpha metabolic nuclear receptor controls growth of colon cancer cells. Carcinogenesis 34 (10), 2253-2261. (Published).
• Coulombe G* , Leblanc C*, Cagnol S*, Maloum F, Lemieux E*, Perreault N , Feng GS , Boudreau F , Rivard N. (2013). Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Molecular and cellular biology 33 (11), 2275-2284. (Published).
• Paquin MC*, Leblanc C*, Lemieux E*, Bian B*, Rivard N. (2013). Functional impact of colorectal cancer-associated mutations in the transcription factor E2F4. International journal of oncology 43 (6), 2015-2022. (Published).
• Jones C , St-Jean S , Fréchette I , Bergeron D , Rivard N , Boudreau F. (2013). Identification of a novel promyelocytic leukemia zinc-finger isoform required for colorectal cancer cell growth and survival. International journal of cancer. 133 (1), 58-66. (Published).
• Cagnol S*, Rivard N. (2013). Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 32 (5), 564-576. (Published).
• Cagnol S*, Boucher MJ, Carrier JC, Rivard N. (2012). Aberrant activation of the KRAS/BRAF/MAP Kinase signalling pathway in colorectal and pancreatic cancers. Médecine/Sciences Amériques 1 86-103. (Published).
• Roy SA , Langlois MJ*, Carrier JC, Boudreau F, Rivard N, Perreault N. (2012). Dual regulatory role for phosphatase and tensin homolog in specification of intestinal endocrine cell subtypes. World journal of gastroenterology : WJG 18 (14), 1579-1589. (Published).
• Paquin MC*, Rivard N. (2012). E2F4 (E2F transcription factor 4, p107/p130 binding). Atlas of Genetics and Cytogenetics in Oncology and Haematology 16 (8), 529-539. (Published).
• Asselin C, Boudreau F, Gendron FP, Perreault N, Rivard N. (2012). Rôle des cellules épithéliales dans le contrôle de l'inflammation intestinale. Médecine/Sciences Amériques 1 86-103. (Published).
• Pinier M*, Fuhrmann G , Galipeau HJ, Rivard N, Murray JA, David CS, Drasarova H, Tuckova L, Leroux JC, Verdu EF. (2012). The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142 (2), 316-325. (Published).
• Lemieux E*, Boucher MJ, Mongrain S*, Boudreau F, Asselin C, Rivard N. (2011). Constitutive activation of the MEK/ERK pathway inhibits intestinal epithelial cell differentiation. American journal of physiology. Gastrointestinal and liver physiology 301 (4), G719-730. (Published).
• Simoneau M*, Coulombe G*, Vandal G*, Vézina A, Rivard N. (2011). SHP-1 inhibits ?-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cellular signalling 23 (1), 269-279. (Published).
• Gaudet S, Langlois MJ*, Lue RA, Rivard N, Viel A. (2011). The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring. BMC cell biology 12 55-62. (Published).
• Lussier CR, Brial F, Roy SA, Langlois MJ*, Verdu EF, Rivard N, Perreault N, Boudreau F. (2010). Loss of hepatocyte-nuclear-factor-1alpha impacts on adult mouse intestinal epithelial cell growth and cell lineages differentiation. PloS one 5 (8), e12378-12385. (Published).
• Langlois MJ*, Bergeron S*, Bernatchez G, Boudreau F, Saucier C, Perreault N, Carrier JC, Rivard N. (2010). The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PloS One 5 (12), 1542. (Published).
• Bergeron S*, Lemieux E*, Durand V*, Cagnol S*, Carrier JC, Lussier JG, Boucher MJ, Rivard N. (2010). The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Molecular cancer 9 271. (Published).
• Lemieux, E., S. Bergeron, V. Durand, C. Asselin, C. Saucier and N. Rivard. (2009). Constitutively active MEK1causes epithelial to mesenchymal transition inintestinal epithelial cells and promotes tumor invasionandmetastasis. Int J Cancer 125 (7), 1575-1586. (Published).
• Garneau, H., M.C. Paquin, J.C. Carrier, and N. Rivard. (2009). E2F4 expression is required for cell cycle progressionof normal intestinal crypt cells and colorectal cancer cells. J Cell Physiology 221 350-358. (Published).
• Langlois, M.J., S.A. Roy, B.A. Auclair, C. Jones, F. Boudreau, J.C. Carrier, N. Rivard and N. Perreault. (2009). Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretorycell commitment and acts as a modifier gene in neoplasia. Faseb J 23 (6), 1835-1844. (Published).
• Siqueira, J.M., A.C. Gazola, M.R. Farias, L. Volkov, N. Rivard, A.J. de Brum-Fernandes, and R.M. Ribeirodo- Valle. (2009). Evaluationof the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivomodels. Cancer Chemother Pharmacol 64 (3), 529-538. (Published).
• Rivard N. (2009). Phosphatidylinositol 3-kinase: a keyregulator in adherens junction formation and function. Frontiers in Biosciences 14 510-522. (Published).
• Pinier, M., E.M. Verdu, M. Nasser-Eddine, N. Rivard* and J.C. Leroux*. (2009). Suppressionof gliadin-induced toxicity by poly(hydroxyethylmethacrylate-co-sodium4-styrene sulfonate): A potential supportive treatment for celiac disease. Gastroenterology 136 (1), 288-298. (Published).

Chapitres de livre

• Paquin MC* and N Rivard. (2012). E2F4 transcription factor. Editor: Jean-Loup Huret, INSERM U 935, Genetics,Dept Medical Information. Atlas of Genetics and Cytogenetics in Oncology and Haematology France : http://AtlasGeneticsOncology.org. (Published).
• Saucier C, Rivard N. (2010). Epithelial cell signalling in colorectal cancer metastasis. Nicole Beauchemin and Jacques Huot. Metastasis of colorectal cancer. (14, 205-242). United States of America : Springer. (Published).

Documents de travail

• Raisch J, MJ Langlois, N Rivard. (2018). The Wnt co-receptor LRP6 reduces inflammation and enhances intestinal regeneration.
• Prinos P, B Chabot, N Rivard. (2016). KRAS signalling modulates EJC complex activity during colorectal carcinogenesis.

Articles de conférence

• Côté-Biron A*, J Gagné-Sansfaçon, and N Rivard. (2023). SHP-2 Activity is required to support oncogenic stress induced by APC tumor suppressor gene mutations. EMBO Workshop: Cancer cell signaling : linking molecular knowledge to cancer therapy. (Published).
• Côté-Biron A*, J Gagné-Sansfaçon, V Vaillancourt-Lavigueur* and N Rivard. (2022). La tyrosine phosphatase SHP-2 : un modulateur de la tumorigénèse induite par l’inactivation du gène suppresseur de tumeurs APC. Signalisation Québec. (Published).
• Chabot V*, A Côté-Biron*, J Gagné-Sansfaçon and N Rivard. (2022). Régulation de la phosphatase SHP-2 par la confluence cellulaire : implication de la voie Hippo?. Signalisation Québec. (Published).
• Lannoy V, J Gagné-Sansfaçon, N Rivard. (2022). SHP-2 active les voies des MAPK en réponse aux ligands des TLRs dans les cellules épithéliales intestinales. ACFAS. (Published).
• Lannoy V*, C Asselin and N Rivard. (2020). SHP-2: a new regulator of Toll-like receptor signaling in intestinal epithelial cells. CIACCO Symposium. (Accepted).
• Lannoy V, J Gagné-Sansfaçon, N Rivard. (2020). SHP-2: a new regulator of Toll-like receptors in intestinal epithelial cells. ASCB. (Published).
• Côté-Biron A, J Raisch et N Rivard. (2019). Role of the Wnt coreceptor LRP6 in KRAS and BRAF-mutated colorectal cancer cells. Chronic Inflammation, Immunity and Cancer International meeting. (Accepted).
• Lannoy V, J Gagné-Sansfaçon, C Asselin, N Rivard. (2019). SHP-2 controls TLR4 and TLR5-dependent MAP Kinase activation in intestinal epithelial cells. Chronic Inflammation, Immunity and Cancer 2019 international meeting. (Accepted).
• Vouillhoz A, J Gagné-Sansfaçon, S Geha, N Rivard. (2019). SHP-2 tyrosine phosphatase: a potential new target for BRAF-dependent cancers?. Chronic Inflammation, Immunity and Cancer 2019 international meeting. (Accepted).
• Leblanc C, D Dion et N Rivard. (2018). Rétrocontrôle de la signalisation Wnt/b-caténine par la tyrosinephosphatase Shp1 dans l’épithélium intestinal. Signalisation Québec 2018. (Accepted).
• Côté-Biron A, J Raisch, N Rivard. (2018). Rôle de LRP6 dans les cellules cancéreuses mutées pour KRAS ou BRAF. Signalisation Québec 2018. (Accepted).
• Côté-Biron A, J Raisch, N Rivard. (2018). Rôle de LRP6 dans l’effet oncogénique de KRAS et de BRAF dans des cellules cancéreuses colorectales. Club de recherches Cliniques du Québec. (Accepted).
• Raisch J, A Côté-Biron, MJ Langlois et N Rivard. (2018). Rôle de LRP6 dans l’homéostasie et l’inflammation intestinale. Signalisation Québec 2018. (Accepted).
• Gagné-Sansfaçon J, A Langlois, MJ Langlois, CK Qu et N Rivard. (2018). SHP-2 confère une résistance à l’inflammation colique en régulant la différenciation des cellules caliciformes et la régénération cellulaire. Signalisation Québec 2018. (Accepted).
• Lannoy V, J Gagné-Sansfaçon, A Langlois, G Coulombe et N Rivard. (2018). SHP-2 contributes to intestinal tolerance to microbiome in a MAPK-dependent manner. Keystone Symposium, Microbiome: Chemical mechanisms and biological consequences. (Accepted).
• Lannoy V, G Coulombe et N Rivard. (2018). SHP-2, un nouveau régulateur des TLRs. Signalisation Québec 2018. (Accepted).
• Lannoy V, A Langlois, G Coulombe, N Rivard. (2018). SHP-2, un nouveau régulateur des TLRs. Club de Recherches Cliniques du Québec. (Accepted).
• Côté-Biron A, J Raisch, and N Rivard. (2018). The Wnt co-receptor LRP6 promotes growth of colorectal cancer cells. Canadian Digestive Diseases Week. (Accepted).
• Raisch J, A Côté-Biron, MJ Langlois and N Rivard. (2017). LRP6 is required for crypt regeneration and for proper intestinal epithelial protection against inflammation. Digestive Diseases Week. (Published).
• Rivard N, V Vaillancourt-Lavigueur, J Gagné-Sansfaçon, MJ Langlois. (2017). SHP-2 promotes intestinal epithelial regenerationand tumorigenesis. Europhosphatases -EMBO Conferences. (Published).
• Raisch J, A Côté-Biron, MJ Langlois, and N Rivard. (2017). The Wnt co-receptor LRP6 reduces inflammation and enhances intestinal regeneration. Canadian Digestive Diseases Week. (Published).
• Langlois MJ, A Langlois, J Gagné-Sansfaçon, C Jones, F Boudreau and N Rivard. (2016). Development of intestinal organoid models to study the cellular functions of Shp-2. Embo Conferences, Organoids: modelling organ development and disease in 3D culture. (Accepted).
• Gagné-Sansfaçon J, S Tremblay, CK Qu, A Menedez and N Rivard. (2016). Epithelial SHP-2 activation protects the intestinal mucosa against colitis induced by dextran sulphate sodium or citrobacterrodentium. Canadian Digestive Diseases Week - CDDW 2016. (Published).
• Gagné-Sansfaçon J, V Vaillancourt-Lavigueur, S Tremblay, CK Qu, A Menendez and N Rivard. (2016). Epithelial SHP-2 protects the intestinal mucosa against colitis and colorectal cancer. BEST PRESENTATION award. Faseb Research Conferences, Protein Phosphatases, Steamboats Springs, Colorado. (Published).
• Gagné-Sansfaçon J, MJ Langlois, CK Qu, and N Rivard. (2016). Functional impact of colorectal cancer-associatedmutations in the tyrosine phosphatase SHP-2. Canadian Digestive Diseases Week - CDDW 2016. (Published).
• Langlois A, MJ Langlois, J Gagné-Sans-façon, C Jones, F Boudreau et N Rivard. (2016). Implication importante de la tyrosine phosphatase Shp-2 dans le développement et lacroissance d’organoïdes intestinaux. Signalisation Québec 2016. (Accepted).
• Gagné-Sansfaçon J, V Vaillancourt-Lavigueur, S Tremblay, CK Qu, A Menendez et N Rivard. (2016). La protéine phosphatase SHP-2 protège la muqueuse intestinale de l’inflammation. Signalisation Québec 2016. (Accepted).
• Beaudry K, A Montagne, MJ Langlois, S Cagnol, and N Rivard. (2016). Role of the phosphatase DUSP6 in the control ofintestinal tumorigenesis and inflammation. CAG Student Prize. Oral presentation. Canadian Digestive Diseases Week, CDDW 2016. (Published).
• Leblanc C, V Vaillancourt-Lavigueur, MJ Langlois, et N Rivard. (2016). Régulation de la croissance cellulaire par la phosphatase Shp-1 et impact sur la tumorigénèse intestinale. Signalisation Québec 2016. (Accepted).
• Leblanc C, MJ Langlois, G Coulombe and N Rivard. (2016). The role of SHP-1 as a tumor suppressor gene inintestinal epithelium. Canadian Digestive Diseases Week, CDDW 2016. (Published).
• Leblanc C, MJ Langlois, N Rivard. (2015). Epithelial tyrosine phosphatase Shp-1 controls growth and secretory cell differentiation in the small intestine. Oral presentation. Gastroenterology, (Published).
• Gagné-Sansfaçon J, G Coulombe, A Langlois, MJ Langlois, M Paquet and N Rivard. (2015). Laphosphatase SHP-2 est un suppresseur de tumeur pour le cancer colorectal associé à la colite. Club de Recherches Cliniques du Québec, CRCQ 2015. (Published).
• Leblanc C, MJ Langlois, N Rivard. (2015). La tyrosine phosphatase Shp-1 régule l’homéostasie de l’épithéliumintestinal en contrôlant l’activation de la voie PI3K/Akt. HANS SELYE Award. Club de Recherches Cliniques du Québec, CRCQ 2015. (Published).
• Langlois A, G Coulombe, MJ Langlois and N Rivard. (2015). L’inactivation de la signalisation TLR/Myd88 atténue l’inflammation intestinale des sourisdéficientes pour l’expression de la phosphatase SHP-2. Club de Recherches Cliniques du Québec. CRCQ 2015. (Published).
• Beaudry K, MJ Langlois, S Cagnol and N Rivard. (2015). Rôlede la phosphatase Dusp6 dans la tumorigénèse et la réponse inflammatoireintestinale. PRIX de la relève. Club de Recherches Cliniques du Québec, CRCQ 2015. (Published).
• Leblanc C, MJ Langlois, G Coulombe, and N Rivard. (2015). SHP-1 protein tyrosine phosphatase negatively modulates growth and Goblet/Paneth cell fate decisions through PI3K/Akt signalling in the intestinal epithelium. Oral presentation. Canadian Digestive Diseases Week. (Published).
• Gagné-Sansfaçon J, G Coulombe, A Langlois, MJ Langlois, M Paquet, and N Rivard. (2015). SHP-2 can act as a tumor suppressor gene in colorectal carcinogenesis. Canadian Digestive Diseases Week. (Published).
• Langlois A, G Coulombe, MJ Langlois, S Cagnol, F Boudreau, G de Palma, P Bercik, EF Verdu and N Rivard. (2015). SHP-2/ERK signalling controls barrier function in the colon. Oral Presentation. Canadian Digestive Diseases Week. (Published).
• Gagné-Sansfaçon J, G Coulombe, A Langlois, MJ Langlois, M Paquet, N Rivard. (2015). Tyrosine phosphatase SHP-2 prevents development of inflammation-associated colon cancer. Oral presentation. Faseb research conferences. Gastrointestinal Tract XVI: GI Homeostasis: The Microbiome and the Barrier, Development, & Disease. (Published).
• Coulombe C, Leblanc C, Langlois MJ, Verdu EF, de Palma G, Bercik P, Rivard N. (2014). Colonic cell fate dysregulation: cause or consequence of inflammation ?. Canadian Digestive Diseases Week. (In Press).
• Gagné-Sanfaçon J, G Coulombe, A Langlois, N Rivard. (2014). La protéine tyrosine phosphatase SHP-2 est un suppresseur de tumeur lors du développement du cancer associé à la colite ulcéreuse. Nominated for Jacques-Genest Prize. Club de recherches cliniques du Québec. (Accepted).
• Langlois A, G Coulombe, N Rivard. (2014). La signalisation SHP-2/ERK/MAP kinase contrôle la détermination cellulaire et promeut la fonction barrière de l’épithélium colique. Club de recherches cliniques du Québec. (Accepted).
• Gagné-Sansfaçon J, G Coulombe, A Langlois, N Rivard. (2014). L’inflammation intestinale engendrée par la deletion de SHP-2 dans l’épithélium promot la tumorigénèse colorectale * Best presentation award, PhD. Signalisation Québec 2014. (Accepted).
• Gagné-Sansfacon J, Coulombe G, Bourdages N, Rivard N. (2014). Role of SHP-2 tyrosine phosphatase in colorectal carcinogenesis. AACR 2014 (American Association of Cancer Research), San Diego, USA. (Published).
• Leblanc C, G Coulombe, N Rivard. (2014). SHP-1 contrôle l’homéostasie de l’épithélium intestinal Best presentation award, MSc. Signalisation Québec. (Accepted).
• Gagné Sanfaçon J, G Coulombe, N Rivard. (2013). Expression et role de la phosphatase SHP-2 dans le cancer colorectal. Club de recherches cliniques du Québec. (Published).
• C Leblanc, G Coulombe, N Rivard. (2013). Implication de la tyrosine phosphatase dans le cancer colorectal. Club de recherches cliniques du Québec. (Published).
• Langlois MJ, Roy SB, Roy E, Carrier J, Perreault N Boudreau F, Rivard N. (2013). Pten and p27 cooperation in intestinal morphogenesis and neoplasia. Keystone Symposia - PI 3-Kinase and Interplay with Other Signaling Pathways (X3). (Accepted).
• Coulombe G, EF Verdu, G de Palma, P Bercik, N Rivard. (2013). SHP-2 contrôle la determination cellulaire de l’épithélium colique. Club de recherches cliniques du Québec. (Accepted).
• Gagné-Sansfacon, J, G Coulombe, N Rivard. (2013). SHP-2 negatively regulates colorectal carcinogenesis. Canadian Digestive Diseases Week. (Published).
• Lemieux, E and N Rivard. (2013). The WNT-b-catenin pathway is involved in KRAS-induced intestinal epithelial cell transformation. Canadian Digestive Diseases Week. Victoria, BC. (Published).
• Lemieux E, Rivard N. (2013). The Wnt/b-catenin pathway contributes to intestinal epithelial cell transformation by oncogenic KRAS/MAPK signalling. Digestive Diseases Week. (Published).
• Coulombe, G, C Leblanc, MJ Langlois, F Boudreau, N Rivard,. (2013). The tyrosine phosphatase SHP-2 regulates inflammation by controlling intestinal epithelial cell response to microflora. Canadian Digestive Diseases Week. (Published).
• Coulombe G, Leblanc C, Langlois MJ, Maloum F, Lemieux E, Perreault N, Feng GS, Boudreau F, Rivard N. (2012). Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation and colorectal cancer. Received a Keystone symposia future of science fund scholarship. Keystone Symposia on molecular and cellular biology. The role of inflammation during carcinogenesis. Dublin, Ireland. (Accepted).
• Montagne A, S Cagnol, N Rivard. (2012). Régulation de la phosphatase DUSP6 par la voie de signalisation RAS-RAF-MEK-ERK lors de la tumorigénèse intestinale. Club de Recherche Clinique du Québec. (Published).
• Coulombe G, C Leblanc, MJ Langlois, F Boudreau, N Rivard. (2012). SHP-2 régule l’inflammation en contrôlant la réponse des cellules épithéliales intestinales à la microflore. Club de Recherche Clinique du Québec. (Published).
• Lemieux E, Rivard N. (2012). The Wnt/b-catenin pathway is involved in KRAS-induced intestinal epithelial cell transformation. American Association for Cancer Research Meeting. (Accepted).
• Lemieux E, G Chevalier-Soudeyns, S Cagnol and N Rivard. (2012). The cyclin-dependent kinase CDK8 is a novel target of ERK signaling involved in human colorectal cancer. Canadian Digestive Diseases Week. (Accepted).
• Coulombe G, S Cagnol, C Leblanc, F Maloum, É Lemieux, F Boudreau and N Rivard. (2012). The tyrosine phosphatase SHP-2 protects against intestinal inflammation. Digestive Disease Week. San Diego. (Published).
• Coulombe G, C Leblanc and N Rivard. (2011). La protéine tyrosine phosphatase SHP-2 contrôle la prolifération et la sénescence des cellules épithéliales intestinale. Club de Recherche Clinique du Québec. (Accepted).
• Chevalier-Soudeyns G, S Cagnol, E Lemieux and N Rivard. (2011). Role of cdk8 in colorectal cancer. ACFAS 2011. (Accepted).
• Coulombe G, C Leblanc, and N Rivard. (2011). SHP-2 protects intestinal epithelial cells against oncogenic stress by inducing senescence. Canadian Digestive Diseases Week. (Accepted).
• Bian B, S Mongrain, F Boudreau and N Rivard. (2011). The role of cathepsin B in colorectal tumorigenesis. AACR, American Association for Cancer Research. (Published).
• Paquin MC and N Rivard. (2010). Dual regulation of E2F4 transcription factor by ERK and GSK3 kinases. ASCB 50th Annual Meeting. (Accepted).
• Bian B, S Mongrain and N Rivard. (2010). Implication de la cathepsine B dans les processus tumorigeniques colorectaux. Club de Recherche Clinique du Québec. 23-25. (Accepted).
• Coulombe G, M Simoneau, and N Rivard. (2010). Regulation of b-catenin function by the tyrosine phosphatase SHP-1 in human intestinal epithelial cells. ASCB 50th Annual Meeting. (Accepted).
• Cagnol S, E Lemieux and N Rivard. (2010). The dual-specificity phosphatases DUSP/MKP: key regulators of the Ras/Raf/ERK pathway in colorectal tumorigenesis. Digestive Diseases Week. (Accepted).
• Paquin MC and N Rivard. (2010). Une forme alternative du co-facteur de transcription DP2 est surexprimée dans les cellules cancéreuses colorectales humaines. Club de Recherche Clinique du Québec. (Accepted).

Autres contributions

Gestion d'évènements

• Co-organizer. (2016) Signalisation Quebec 2016. (Conference).
• Co-organizer. (2015) 54ième Réunion annuelle du Club de Recherches Cliniques du Québec, Orford, Québec. (Conference).
• Co-organizer. (2014) 55ième Réunion annuelle du Club de Recherches Cliniques du Québec, Lac Delage, Québec. (Conference).
• Co-organizer. (2014) 55ième Réunion annuelle du Club de Recherches Cliniques du Québec, Ste-Adèle, Québec. (Conference).
• Co-organizer. (2010) 4th Symposium Signalisation Québec. (Conference).

Activités de collaboration internationale

• Collaborator with Cheng-Kui Qu. United States of America.
• Collaborator with GS Feng. United States of America.
• Collaborator with M. Chamaillard. France.
• Collaborator with JC Leroux. Switzerland.

Présentations

• (2023). The tyrosine phosphatase Shp-2: a new target for colon inflammation and cancer?. Colloque au Centre de cancérologie de Lyon. France
• (2022). Regulation of TLR4-dependent signaling pathways by Shp-2: impact on colon inflammation!. Signalisation Quebec. Canada
• (2022). Role of Shp-2 phosphatase in Raf-induced colorectal cancer. Cancer World Congress. Portugal
• Côté-Biron A*, J Gagné Sansfaçon and N Rivard. (2022). SHP-2 Activity is required to support oncogenic stress induced by APC tumor suppressor gene mutations. EMBO Workshop: Cancer cell signaling : linking molecular knowledge to cancer therapy. Croatia
• Rivard N. (2019). SHP-2 phosphatase contributes to mucosal tolerance to microbiota in the colon. Canadian Digestive Diseases Week 2019, Banff. Canada
• (2018). Rôle de LRP6 dans l'action pro-oncogénique de la signalisation Ras/MAP kinase. Signalisation QUÉBEC 2018. Bécancour, Canada
• Rivard N, V Vaillancourt-Lavigueur, J Gagé-Sansfaçon, MJ Langlois. (2018). SHP-2 promotes intestinal epithelial regeneration and tumorigenesis. Europhosphatases: Phosphatases in cell fates and decisions. Embo Conference. Paris, France
• Rivard N. (2017). Complex regulation of ERK signaling during colorectal carcinogenesis. KEYNOTE Lecture. 10th Annual Cancer Congress. Barcelona, Spain
• (2017). Shp-2 : une phosphatase au cœur de l’inflammation et du cancer du côlon. Conférencière invitée, Département de Pharmacologie, Université de Montréal. Montréal, Canada
• Rivard N. (2016). Epithelial SHP-2 protects the intestinal mucosa against colitis and colorectal cancer. KEYNOTE Lecture. 7th European Pediatrics Conference, Amsterdam. Amsterdam, Netherlands
• (2016). SHP-2 est-il un oncogène pour l’épithélium intestinal ?. Signalisation Québec 2016. Bécancour, Canada
• Rivard N. (2016). The complex role of SHP-2 tyrosine phosphatase in the development of colorectal cancer. KEYNOTE Lecture. 6th Global Gastroenterologists meeting. Birmingham, United Kingdom
• (2016). The complex role of SHP-2 tyrosine phosphatase in the development of colorectal cancer. KEYNOTE Lecture. 8th International Conference on Clinical Gastroenterology & Hepatology,. Toronto, Canada
• Leblanc C, MJ Langlois, N Rivard. (2015). Epithelial tyrosine phosphatase Shp-1 controls growth and secretory cell differentiation in the small intestine. Digestive Diseases Week. Washington, United States of America
• (2015). La phosphatase SHP-2 contrôle la fonction barrière de l'épithélium intestinal. Conférence invitée au LOEX, Université Laval. Québec, Canada
• Rivard N. (2015). Oncogenic KRAS promotes the Wnt/b-catenin signaling pathway through LRP6 during colorectal oncogenesis. 20th World Congress on Advances in Oncology & 18th International Symposium of molecular medicine. Athènes, Greece
• (2015). SHP-2, a tyrosine phosphatase that protects against inflammation and cancer in the colon. KEYNOTE Lecture. Canadian Digestive Diseases Week 2015 (Symposium Inflammation-Cancer). Banff, Canada
• (2015). The dual functions of SHP-2 tyrosine phosphatase in colorectal cancer. Atelier sur la recherche en cancer- National Science Foundation of China (NSFC)-FRQS. Shanghai, China
• (2014). Dual functions of SHP-2 tyrosine phosphatase in colorectal cancer. Cancer Science 2014. Chicago, United States of America
• Leblanc C, Coulombe G, Langlois MJ, Rivard N. (2014). Involvement of the SHP-1 tyrosine phosphatase in regulating intestinal epithelial cell signaling, proliferation and tumorigenesis. Canadian Digestive Diseases Week. Toronto, Canada
• N Rivard. (2014). Protein tyrosine phosphatases in the intestinal epithelium: emerging regulators of inflammation and tumorigenesis. 35th Anniversary Symposium "Growth Control Lab". Nice, France
• (2014). Role of SHP-2 phosphatase in the regulation of intestinal homeostasis. Conférence invitée à l'INSERM UMR-1043, Centre de pathophysiologie de Toulouse Purpan. Toulouse, France
• (2014). SHP-2 régule l'inflammation en contrôlant la réponse des cellules épithéliales intestinales à la microflore. Signalisation Québec 2014. Bécancour, Canada
• (2014). Understanding the dual nature of SHP-2 in colorectal cancer. 19th World Congress on Advances in Oncology & 17th Internation Symposium of molecular medicine. Athènes, Greece
• Rivard N. (2013). A role for DUSP4 phosphatase in colorectal carcinogenesis ?. The Rosalind and Morris Goodman Cancer Research Centre, Montreal. Montréal, Canada
• Rivard N. (2013). Contribution de la signalisation Wnt/b-caténine dans l'effet oncogénique de la voie KRAS/MAP Kinase. ACFAS 2013, Colloque sur l'oncologie. Québec, Canada
• Langlois MJ, Roy SB, Roy E, Carrier J, Perreault N Boudreau F, Rivard N. (2013). Pten and p27 cooperation in intestinal morphogenesis and neoplasia. Keystone Symposia - PI 3-Kinase and Interplay with Other Signaling Pathways (X3). Keystone, United States of America
• Rivard, N. (2013). Signalling pathways in intestinal epithelial cells: decisions to cycle, to differentiate, to transform and to inflame. Canadian Digestive Diseases Week (Research Excellence Lecture). Victoria, Canada
• Langlois MJ, SB Roy, E Roy, N Perreault, F Boudreau, N Rivard. (2012). Coopération de PTEN et de p27 dans le maintien de l’homéostasie intestinale. Club de Recherche Clinique du Québec, Orford. Orford, Canada
• Placet M, G Chevalier-Soudeyns, E Lemieux, C Asselin, N Rivard. (2012). Rôle de CDK8 dans la tumorigénèse colorectale. Club de Recherche Clinique du Québec, Orford. Orford, Canada
• Coulombe G, C Leblanc, MJ Langlois, F Boudreau, N Rivard. (2012). SHP-2 régule l’inflammation en contrôlant la réponse des cellules épithéliales intestinales à la microflore. Club de Recherche Clinique du Québec, Orford. Orford, Canada
• Coulombe C, S Cagnol, C Leblanc, F Maloum, É Lemieux, F Boudreau, N Rivard. (2012). The tyrosine phosphatase SHP-2 protects against intestinal inflammation. Digestive Disease Week, San Diego. San Diégo, United States of America
• Rivard N. (2012). Un rôle pour DUSP4 dans la carcinogénèse colorectale ?. Signalisation Québec 2012, Bécancour QC. Bécancour, Canada
• Rivard N. (2011). Cooperative regulation of the metastatic potential by the PI3K and ERK signaling pathways. Montreal International Symposium on Angiogenesis and Metastasis (MISAM 2011). Montréal, Canada
• Rivard N. (2011). Epithelial cell signalling in colorectal carcinogenesis. 1st International symposium in digestive physiopathology. Orford, Canada
• Rivard N. (2011). Implications de la phosphorylation et la surexpression du facteur de transcription E2F4 dans la tumorigénèse intestinale. ACFAS 2011, Sherbrooke. Sherbrooke, Canada
• Cagnol S, Rivard N. (2011). La phosphatase nucléaire MKP2/DUSP4 est un régulateur crucial de la voie Ras/RAF/ERK dans la tumorigenèse colorectale. Club de Recherche Clinique du Québec, Sainte-Adèle. Sainte-Adèle, Canada
• Rivard N. (2011). Role of DUSPs in colorectal carcinogenesis. 16th World Congress on advances in oncology & 14th international Symposium on molecular medicine. Rhodes, Greece. Rhodes, Greece, Greece
• Rivard N. (2011). Rôle et régulation du sentier de signalisation ERK MAP Kinases dans la carcinogénèse colorectale. Centre de recherche sur le cancer de l’Hôtel-Dieu de Québec. Québec, Canada
• Coulombe G, E Lemieux, F Boudreau, N Rivard. (2011). The tyrosine phosphatase SHP-2 protects against intestinal inflammation. Canadian Digestive Diseases Week, Vancouver, Canada Recipient of Canadian of the Association of Gastroenterology Student Research Prize. Vancouver, Canada
• N Rivard. (2010). Role SHP-2 in the control of intestinal inflammation. Hôpital Ste-Justine, Université de Montréal. Canada
• N Rivard. (2010). Role of PTEN in colorectal carcinogenesis. 15th World Congress on advances in oncology & 13th international Symposium on molecular medicine. Athens, Greece
• Cagnol S, Lemieux, Rivard N. (2010). The dual-specificity phosphatases DUSP/MKP: key regulators of the Ras/Raf/ERK pathway in colorectal tumorigenesis. Canadian Digestive Diseases Week. Toronto, Canada